孔维霞,张峰,杨金雨,周英,郭琦,郭萌,蒋超,杨青

• 1:郑州大学第五附属医院
• 2:河南省人民医院

摘要(Abstract)：

目的 探讨中性粒细胞/高密度脂蛋白胆固醇比值（NHR）与无症状性颈动脉狭窄斑块稳定性的关系。方法 前瞻性纳入2022-01—2024-06郑州大学第五附属医院门诊诊断为无症状性颈动脉狭窄的117例患者，根据患者颈动脉斑块稳定性将其分为斑块稳定组与斑块不稳定组，分别比较2组患者中性粒细胞绝对值、血清高密度脂蛋白胆固醇水平、NHR，分析NHR与颈动脉斑块稳定性的关系。结果 斑块稳定组与斑块不稳定组中性粒细胞绝对值分别为（3.43±0.78）×10~9个/L、（3.51±1.15）×10~9个/L，血清高密度脂蛋白胆固醇水平分别为（1.83±0.64）mmol/L、（1.69±0.69）mmol/L,NHR分别为1.77±0.39、2.11±0.46,2组NHR比较差异有统计学意义（P<0.05）。二元Logistic回归与ROC曲线分析表明，NHR为无症状性颈动脉狭窄斑块不稳定的独立危险因素（OR=4.743,P<0.001），且NHR对不稳定颈动脉斑块的诊断可能具有较好的预测价值（AUC=0.930）。结论 NHR可预测无症状性颈动脉狭窄斑块的不稳定性，临床可能具有一定价值。

关键词(KeyWords)： 无症状性颈动脉狭窄;炎症;脂质代谢;斑块稳定性;中性粒细胞/高密度脂蛋白胆固醇比值;相关性

Abstract:

Keywords:

基金项目(Foundation): 河南省中青年卫生健康科技创新人才培养项目(编号:YXKC2020020)

作者(Author): 孔维霞,张峰,杨金雨,周英,郭琦,郭萌,蒋超,杨青

参考文献(References)：

• [1] MARTIN S S,ADAY A W,ALMARZOOQ Z I,et al. 2024 Heart Disease and Stroke Statistics:A Report of US and Global Data From the American Heart Association[J]. Circulation,2024,149(8):e347-e913.
• [2] KARASAWA T,TAKAHASHI M. Inflammasome Activation and Neutrophil Extracellular Traps in Atherosclerosis[J]. J Atheroscler Thromb,2025,32(5):535-549.
• [3] WANG X,XIE Z,ZHANG J,et al. Interaction between lipid metabolism and macrophage polarization in atherosclerosis[J].iScience,2025,28(4):112168.
• [4] OKAN T,TOPALOGLU C. Association of ratios of monocyte/high-density lipoprotein cholesterol and neutrophil/high-density lipoprotein cholesterol with atherosclerotic plaque type on coronary computed tomography[J]. Cardiovasc J Afr,2024,34:1-6.
• [5] GKANTZIOS A,TSIPTSIOS D,KARAPEPERA V,et al. Monocyte to HDL and Neutrophil to HDL Ratios as Potential Ischemic Stroke Prognostic Biomarkers[J]. Neurol Int,2023,15(1):301-317.
• [6] LAMICHHANE P,AGRAWAL A,ABOUAINAIN Y,et al. Utility of neutrophil-to-high-density lipoprotein-cholesterol ratio in patients with coronary artery disease:a narrative review[J]. J Int Med Res,2023,51(4):3000605231166518.
• [7] POWERS W J, RABINSTEIN A A, ACKERSON T, et al.Guidelines for the Early Management of Patients With Acute Ischemic Stroke:2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke,2019,50(12):e344-e418.
• [8] BAUMER Y,IREI J,BOISVERT W A. Cholesterol crystals in the pathogenesis of atherosclerosis[J]. Nat Rev Cardiol,2025,22(5):315-332.
• [9] XING Y,LIN X. Challenges and advances in the management of inflammation in atherosclerosis[J]. J Adv Res,2025,71:317-335.
• [10] VRIEND E M C,GALENKAMP H,VAN VALKENGOED I G M, et al. Sex disparities in hypertension prevalence, blood pressure trajectories and the effects of anti-hypertensive treatment[J]. Blood Press,2024,33(1):2365705.
• [11] CHAN J C N,YANG A,CHU N,et al. Current type 2 diabetes guidelines:Individualized treatment and how to make the most of metformin[J]. Diabetes Obes Metab,2024,26(Suppl 3):55-74.
• [12] YU L, MA K, HAO J, et al. Neutrophil to high-density lipoprotein cholesterol ratio,a novel risk factor associated with acute ischemic stroke[J]. Medicine(Baltimore),2023,102(26):e34173.
• [13] CHEN G, YANG N, REN J, et al. Neutrophil Counts to High-Density Lipoprotein Cholesterol Ratio:a Potential Predictor of Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis[J]. Neurotox Res,2020,38(4):1001-1009.
• [14] ZHAO Z,WANG H,HOU Q,et al. Non-traditional lipid parameters as potential predictors of carotid plaque vulnerability and stenosis in patients with acute ischemic stroke[J]. Neurol Sci,2023,44(3):835-843.
• [15] CHEN G, YANG N, REN J, et al. Neutrophil Counts to High-Density Lipoprotein Cholesterol Ratio:a Potential Predictor of Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis[J]. Neurotox Res,2020,38(4):1001-1009.
• [16] QIN M,LIU T,SHI X,et al. Antiplatelet therapy versus intravenous thrombolysis for mild acute ischaemic stroke:a living systematic review and meta-analysis[J]. Stroke Vasc Neurol,2025,10(2):e003097.
• [17] KWOK G Y R,CHEN R W R,LEOW T A,et al. Recurrent ischaemic stroke in young adults:a multi-centre cohort study,systematic review and meta-analysis[J]. Int J Stroke,2025,17474930251340799.
• [18]蒋超，王月娟，张静，等.急性颈内动脉系统脑梗死患者侧支循环建立情况与预后关系的研究[J].中华行为医学与脑科学杂志，2017,26(7):615-619.
• [19] LI Y,FENG Q,WANG L,et al. Current targeting strategies and advanced nanoplatforms for atherosclerosis therapy[J]. J Drug Target,2024,32(2):128-147.
• [20] MADAUDO C, COPPOLA G, PARLATI A L M, et al.Discovering Inflammation in Atherosclerosis:Insights from Pathogenic Pathways to Clinical Practice[J]. Int J Mol Sci,2024,25(11):6016.
• [21]李法强，纪艾玲，王帅帅.急性缺血性脑血管病患者脑动脉粥样硬化性狭窄分布及危险因素[J].中国实用神经疾病杂志，2023,26(3):339-343.
• [22] AMMIRATI E,MORONI F,NORATA G D,et al. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis[J]. Mediators Inflamm,2015,2015:718329.
• [23] TIAN W,JU J,GUAN B,et al. Role of hyperhomocysteinemia in atherosclerosis:from bench to bedside[J]. Ann Med,2025,57(1):2457527.
• [24] RAGGI P,QUYYUMI A A,HENEIN M Y,et al. Psychosocial stress and cardiovascular disease[J]. Am J Prev Cardiol,2025,22:100968.
• [25] LI Y,GONG S,YAN K,et al. Artery tertiary lymphoid organs in atherosclerosis:A review[J]. Life Sci,2025,369:123549.
• [26] SALLAM M,HASSAN H,CONNOLLY D,et al. Commencement of Atorvastatin and Ezetimibe Immediately in Patients Presenting with Acute Coronary Syndrome[J]. Eur Cardiol,2024,19:e22.
• [27] UEKI Y,ITAGAKI T,KUWAHARA K. Lipid-lowering Therapy and Coronary Plaque Regression[J]. J Atheroscler Thromb,2024,31(11):1479-1495.
• [28] CLEZAR C N, FLUMIGNAN C D, CASSOLA N, et al.Pharmacological interventions for asymptomatic carotid stenosis[J]. Cochrane Database Syst Rev,2023,8(8):CD013573.
• [29] BORGHI C, LEVY B I. Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis[J]. Nutr Metab Cardiovasc Dis,2022,32(4):815-826.
• [30]董楠，吴璇，方琪.动脉粥样硬化抗炎治疗的干预靶点探索[J].中华神经科杂志，2023,56(11):1318-1324.
• [31] UGUSMAN A, HISAM N S N, OTHMAN N S, et al.Pharmacological interventions for intraplaque neovascularization in atherosclerosis[J]. Pharmacol Ther,2024,261:108685.
• [32] HAFIANE A,DASKALOPOULOU S S. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis[J]. Pharmacol Res,2022,178:106157.
• [33] D?RING Y,VAN DER VORST E P C,WEBER C. Targeting immune cell recruitment in atherosclerosis[J]. Nat Rev Cardiol,2024,21(11):824-840.
• [34] ROMAN Y M,HERNANDEZ A V,WHITE C M. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease[J]. Ann Pharmacother,2020,54(10):1021-1029.
• [35] ZHENG W C,CHAN W,DART A,et al. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease[J]. Eur Heart J Cardiovasc Pharmacother,2024,10(1):53-67.
• [36] KARNEWAR S,KARNEWAR V,DEATON R A,et al. IL-1βInhibition Partially Negates the Beneficial Effects of Diet-Induced Atherosclerosis Regression in Mice[J]. Arterioscler Thromb Vasc Biol,2024,44(6):1379-1392.
• [37] HEMENWAY G,FRISHMAN W H. Therapeutic Implications of NLRP3-Mediated Inflammation in Coronary Artery Disease[J].Cardiol Rev,2022,30(2):90-99.
• [38] BURGER F, BAPTISTA D, ROTH A, et al. NLRP3Inflammasome Activation Controls Vascular Smooth Muscle Cells Phenotypic Switch in Atherosclerosis[J]. Int J Mol Sci,2021,23(1):340.
• [39] PENNA C, PAGLIARO P. Endothelial Dysfunction:Redox Imbalance,NLRP3 Inflammasome,and Inflammatory Responses in Cardiovascular Diseases[J]. Antioxidants(Basel),2025,14(3):256.
• [40] SUN L, ZHU Y, YUAN Y. NLRs in tumor chemotherapy resistance:A double-edged sword[J]. Chem Biol Interact,2025,414:111499.
• [41] GUO L,CAO X,CHANG L,et al. Neutrophil-to-lymphocyte ratio as a predictor of prognosis in patients with spontaneous intracerebral hemorrhage:a systematic review and meta-analysis[J]. Front Neurol,2025,16:1553263.
• [42] GHASEMPOUR DABAGHI G,RABIEE RAD M,MORTAHEB M, et al. The Neutrophil-to-Lymphocyte Ratio Predicts Cardiovascular Outcomes in Patients With Diabetes:A Systematic Review and Meta-Analysis[J]. Cardiol Rev,2025,33(3):202-211.